Use of the Chartis® Assessment System prior to EBV Treatment
This is a multi-center study which will enroll up to 120 patients. Subjects will undergo a Chartis Assessment prior to EBV treatment. The Chartis assessment will determine the presence or absence of collateral ventilation, a potential determining factor in the success of EBV therapy. This study is not randomized; all subjects are eligible to receive EBV Treatment, regardless of Chartis Assessment outcome. Follow-up data will only be collected on those patients that meet the Chartis inclusion criteria.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
96
The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
The endobronchial valve is designed to induce target lobe volume reduction.
University of Heidelberg
Heidelberg, Germany
UMC Groningen
Groningen, Netherlands
Lung Volume Change
Time frame: 30 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.